Filing Flows › Comparisons › MGX vs LCTX
Metagenomi Therapeutics vs Lineage Cell Therapeutics: MGX and LCTX compared
Metagenomi Therapeutics is the larger company: $1.2M of revenue in its latest quarter (Q1 2026) against $1.1M for Lineage Cell Therapeutics (Q2 2026). Lineage Cell Therapeutics is growing faster (-61% against -70% a year earlier).
Where the money goes: MGX and LCTX
Metagenomi Therapeutics (MGX) · Q1 2026
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
Lineage Cell Therapeutics (LCTX) · Q2 2026
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Metagenomi Therapeutics (MGX) | Lineage Cell Therapeutics (LCTX) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $1.2M | $1.1M |
| Revenue growth, Y/Y | -70% | -61% |
| Operating margin | n/m | -834.7% |
| Net earnings | −$23.1M | $1.5M |
| Net margin | — | 144.4% |
| Operating cash flow | −$21.2M | −$7.2M |
Where the revenue comes from
Lineage Cell Therapeutics
- Collaboration Revenues: $943K (88%)
- Royalties License and Other Revenues: $126K (12%)
Questions
Which is bigger, Metagenomi Therapeutics or Lineage Cell Therapeutics?
Metagenomi Therapeutics is the larger company: $1.2M of revenue in its latest quarter (Q1 2026) against $1.1M for Lineage Cell Therapeutics (Q2 2026).
Is Metagenomi Therapeutics or Lineage Cell Therapeutics growing faster?
Lineage Cell Therapeutics is growing faster (-61% against -70% a year earlier).
More: Metagenomi Therapeutics earnings · how Metagenomi Therapeutics makes money · Lineage Cell Therapeutics earnings · how Lineage Cell Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 11, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.